Hemophilia A — Early Prophylaxis Immunologic Challenge (EPIC) Study
Citation(s)
A Phase 3b Clinical Study to Assess Whether Regular Administration of ADVATE in the Absence of Immunological Danger Signals Reduces the Incidence Rate of Inhibitors in Previously Untreated Patients With Hemophilia A